PUBLICATIONS

Our science supports everything we do. We are proud of the publications our company and collaborators have generated, and we will continue to be active contributors to the scientific community.

  • Clinical Utility
  • Clinical Validity
  • Health Economics
  • Analytical Validity
  • All Studies
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
NATURE GENETICS, 2017
Collin M Blakely, Thomas B K Watkins, Wei Wu, Beatrice Gini, Jacob J Chabon, Caroline E McCoach, Nicholas McGranahan, Gareth A Wilson, Nicolai J Birkbak, Victor R Olivas, Julia Rotow, Ashley Maynard, Victoria Wang, Matthew A Gubens, Kimberly C Banks, Richard B Lanman, Aleah F Caulin, John St John, Anibal R Cordero, Petros Giannikopoulos, Andrew D Simmons, Philip C Mack, David R Gandara, Hatim Husain, Robert C Doebele, Jonathan W Riess, Maximilian Diehn, Charles Swanton & Trever G Bivona
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
CLINICAL CANCER RESEARCH, 2017
Yulian Khagi, Aaron M. Goodman, Gregory A. Daniels, Sandip P. Patel, Assuntina G. Sacco, James M. Randall, Lyudmila A. Bazhenova and Razelle Kurzrock
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
CLINICAL CANCER RESEARCH, 2017
Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew P. Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy J. Pluard, Carey Anders, Polly Ann Niravath, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly C. Banks, Richard B. Lanman, Richard Bryce, Alshad S. Lalani, John Pfeifer, Daniel F. Hayes, Mark Pegram, Kimberly Blackwell, Philippe L. Bedard, Hussam Al-Kateb and Matthew J.C. Ellis
Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients
CLINICAL CANCER RESEARCH, 2017
Yuebi Hu, Ryan S. Alden, Justin I. Odegaard, Stephen R. Fairclough, Ruthia Chen, Jennifer Heng, Nora Feeney, Rebecca Nagy, Jayshree Shah, Bryan Ulrich, Martin Gutierrez, Richard B. Lanman, Judy E. Garber, Cloud P. Paweletz and Geoffrey R. Oxnard
Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing
CANCER RESEARCH, 2017
Maria Schwaederle, Ranajoy Chattopadhyay, Shumei Kato, Paul T Fanta, Kimberly C. Banks, In Sil Choi, David E Piccioni, Sadakatsu Ikeda, AmirAli Talasaz, Richard B. Lanman, Lyudmila Bazhenova and Razelle Kurzrock
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
CANCER RESEARCH, 2017
Shumei Kato, Nithya Krishnamurthy, Kimberly C. Banks, Pradip De, Kirstin Williams, Casey Williams, Brian Leyland-Jones, Scott M. Lippman, Richard B. Lanman and Razelle Kurzrock
Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
Kidney Cancer, 2017
Manuel Caitano Maia, Paulo Gustavo Bergerot, Nazli Dizman, JoAnn Hsu, Jeremy Jones, Richard B. Lanman, Kimberly C. Banks, and Sumanta K. Pal
Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
JCO Precision Oncology, 2017
Seung Tae Kim, Kimberly C. Banks, Se-Hoon Lee, Kyung Kim, Joon Oh Park, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Richard B. Lanman, AmirAli Talasaz, Keunchil Park, and Jeeyun Lee
Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma
Clinical Cancer Research, 2017
Maria Schwaederle, Sandip P. Patel, Hatim Husain, Megumi Ikeda, Richard Lanman, Kimberly C. Banks, AmirAli Talasaz, Lyudmila Bazhenova and Razelle Kurzrock
MET exon 14 mutation encodes an actionable therapeutic target in lung adenocarcinoma
Cancer Research, 2017
Xinyuan Lu, Nir Peled, John Greer, Wei Wu, Peter Choi, Alice H Berger, Sergio Wong, Kuang-Yu Jen, Youngho Seo, Byron Hann, Angela Brooks, Matthew Meyerson and Eric A Collisson
Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer
Breast Cancer Research and Treatment, 2017
Kara N. MaxwellDanielle Soucier-ErnstEmin TahirovicAndrea B. TroxelCandace ClarkMichael FeldmanChristopher ColamecoBijal KakrechaMelissa LangerDavid LiebermanJennifer J. D. MorrissetteMatt R. PaulTien-chi PanStephanie YeeNatalie ShihErica CarpenterLewis A. ChodoshAngela DeMichele
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages
Journal of Hematology & Oncology, 2017
Meng Yang, Umit Topaloglu, W. Jeffrey Petty, Matthew Pagni, Kristie L. Foley, Stefan C. Grant, Mac Robinson, Rhonda L. Bitting, Alexandra Thomas, Angela T. Alistar, Rodwige J. Desnoyers, Michael Goodman, Carol Albright, Mercedes Porosnicu, Mihaela Vatca, Shadi A. Qasem, Barry DeYoung, Ville Kytola, Matti Nykter, Kexin Chen, Edward A. Levine, Edgar D. Staren, Ralph B. D’AgostinoJr, Robin M. Petro, William Blackstock, Bayard L. Powell, Edward Abraham, Boris Pasche, and Wei Zhang
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma
European Urology, 2017
Sumanta K. Pal'Correspondence information about the author Sumanta K. PalEmail the author Sumanta K. Pal, Guru Sonpavde, Neeraj Agarwal, Nicholas J. Vogelzang, Sandy Srinivas, Naomi B. Haas, Sabina Signoretti, Bradley A. McGregor, Jeremy Jones, Richard B. Lanman, Kimberly C. Banks, Toni K. Choueiri
Genomic profiling of advanced non-small cell lung cancer in community settings: Gaps and Opportunities
Clinical Lung Cancer, 2017
Martin E. Gutierrez, Kelly Choi, Richard B. Lanman, Edward J. Licitra, Stanley M. Skrzypczak, Ruth Pe Benito, Tommy Wu, Srikesh Arunajadai, Sukhi Kaur, Harry Harper, Andrew L. Pecora, Eric V. Schultz, Stuart L. Goldberg
An acquired HER2 1 T798I gatekeeper mutation induces resistance to neratinib in a patient with 2 HER2 mutant-driven breast cancer
Cancer Discovery, 2017
Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler and Carlos L. Arteaga
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
The Lancet Oncology, 2017
Van K Morris, MD, Mohamed E Salem, MD, Halla Nimeiri, MD, Syma Iqbal, MD, Preet Singh, MD, Kristen Ciombor, MD, Blase Polite, MD, Dustin Deming, MD, Emily Chan, MD, James L Wade, MD, Lianchun Xiao, MS, Prof Tanios Bekaii-Saab, MD, Luis Vence, PhD, Jorge Blando, DVM, Armeen Mahvash, MD, Wai Chin Foo, MD, Chimela Ohaji, MD, Manolo Pasia, BSN, Gail Bland, BS, Aki Ohinata, PAC, Jane Rogers, PharmD, Amir Mehdizadeh, MA, Kimberly Banks, MS, Richard Lanman, MD, Prof Robert A Wolff, MD, Howard Streicher, MD, Prof James Allison, PhD, Prof Padmanee Sharma, MD, Prof Cathy Eng, MD
Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer
Journal of Thoracic Oncology, 2017
Nir Peled, MD, PhD, Laila C. Roisman, PhD, Benjamin Miron, MD, Raphael Pfeffer, MD, Richard B. Lanman, MD, Maya Ilouze, PhD, Addie Dvir, Lior Soussan-Gutman, Fabrice Barlesi, MD, PhD, Gabi Tarcic, PhD, Oded Edelheit, PhD, David Gandara, MD, Yehiel Elkabetz, PhD
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Cancer Discovery, 2017
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy and Andrew X. Zhu
All IssuesUp Arrow In This IssueDown Arrow Left ArrowPrevious Article Next ArticleRight Arrow Thyroid About This Journal... Subscribe... Buy Article... Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma
Thyroid, 2017
Vlad C. Sandulache, Michelle D. Williams, Stephen Y. Lai,1, Charles Lu, William N. William, Naifa L. Busaidy, Gilbert J. Cote, Rajesh R. Singh, Rajyalakshmi Luthra, and Maria E. Cabanillas
Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer
Journal of Thoracic Oncology, 2016
Anna Belilovski Rozenblum, MD, Maya Ilouze, PhD, Elizabeth Dudnik, MD, Addie Dvir, MSc, Lior Soussan-Gutman, PhD, Smadar Geva, MSc, Nir Peled, MD, PhD
Genomic Tissue Analysis and Liquid Biopsy Profiles from Patients Diagnosed with Advanced Adenocarcinoma of the Lung
Clinics in Oncology, 2016
Edgardo S. Santos, Luis E. Raez , Lilibeth Del Carmen Castillero , Camila Marana, and Brian Hunis
Phase 1B Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation
Cancer Discovery, 2016
David S. Hong, Van K. Morris, Badi El Osta, Alexey V. Sorokin, Filip Janku, Siqing Fu, Michael J. Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee, Apostolia Tsimberidou, David Fogelman, Jorge Bellido, Imad Shureiqi, Helen Huang, Johnique Atkins, Gabi Tarcic, Nicolas Sommer, Richard Lanman, Funda Meric-Bernstam, Scott Kopetz
Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA
Clinical Cancer Research, 2016
Jeffrey C Thompson, Stephanie S Yee, Andrea B Troxel, Samantha L Savitch, Ryan Fan, David Balli, David B Lieberman, Jennifer D Morrissette, Tracey L Evans, Joshua Bauml, Charu Aggarwal, John A Kosteva, Evan Alley, Christine Ciunci, Roger B Cohen, Stephen Bagley, Susan Stonehouse-Lee, Victoria E Sherry, Elizabeth Gilbert, Corey Langer, Anil Vachani, Erica L Carpenter
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
Oncotarget, 2016
Victoria Villaflor, Brian Won, Rebecca Nagy, Kimberly Banks, Richard B. Lanman, AmirAli Talasaz, Ravi Salgia
Costs of the Diagnostic Workup for Lung Cancer: A Medicare Claims Analysis
Clinical Lung Cancer, 2016
Tasneem Lokhandwala, Marisa A. Bittoni, Robert Dann, Anna O. D’Souza, Meridith Johnson, Rebecca J. Nagy, Richard B. Lanman, Robert Merritt, David Carbone
MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon
Oncotarget, 2016
Kanwal Raghav, Van Morris, Chad Tang, Pia Morelli, Hesham M. Amin, Ken Chen, Ganiraju C Manyam, Bradley Broom, Michael J. Overman, Kenna Shaw, Funda Meric-Bernstam, Dipen Maru, David Menter, Lee M Ellis, Cathy Eng, David Hong, Scott Kopetz
Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
Clinical Cancer Research, 2067
Maria Schwaederle, Hatim Husain, Paul T. Fanta, David E. Piccioni, Santosh Kesari, Richard B. Schwab, Sandip P. Patel, Olivier Harismendy, Megumi Ikeda, Barbara A. Parker, Razelle Kurzrock
Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer
Journal of Thoracic Oncology, 2016
Zofia Piotrowska, Benjamin Drapkin, Jeffrey A. Engelman, Rebecca J. Nagy, Richard B. Lanman, Lecia V. Sequist
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
Oncotarget, 2016
Maria Schwaederle, Hatim Husain, Paul T. Fanta, David E. Piccioni, Santosh Kesari, Richard B. Schwab, Kimberly C. Banks, Richard B. Lanman, AmirAli Talasaz, Barbara A. Parker, Razelle Kurzrock
Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Breast Cancer Research and Treatment, 2015
Diana H. Liang, Joe E. Ensor, Zhe-bin Liu, Asmita Patel, Tejal A. Patel, Jenny C. Chang, Angel A. Rodriguez
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
PLoS ONE, 2015
Richard B. Lanman, Stefanie A. Mortimer, Oliver A. Zill, Dragan Sebisanovic, Rene Lopez, Sibel Blau, Eric A. Collisson, Stephen G. Divers, Dave S. B. Hoon, Scott Kopetz, Jeeyun Lee, Petros Nikolinakos, Arthur M. Baca, Bahram G. Kermani, Helmy Eltoukhy, AmirAli Talasaz
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK Plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Clinical Cancer Research, 2015
Andrew H. Ko, Tanios Bekaii-Saab, Jessica van Ziffle, Olga K Mirzoeva, Nancy Joseph, AmirAli Talasaz, Peter Kuhn, Margaret A. Tempero, Eric Collisson, Robin K. Kelley, Alan Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya, Sanaa Tahiri, and W. Michael Korn
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Cancer Discovery, 2015
Oliver A. Zill, Claire Greene,Dragan Sebisanovic, Laimun Siew, Jim Leng,Mary Vu, Andrew E. Hendifar, Zhen Wang, Chloe E. Atreya, Robin K. Kelly, Katherine Van Loon, Andrew H. Ko, Margaret A. Tempero, Trever G. Bivona, Pamela N. Munster, Amir Ali Talasaz, Eric A. Collisson
1
2
3
...

2017 Guardant Health, Inc.
All Rights Reserved. Legal/Privacy